This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
TEX14 Polyclonal Antibody
catalog :
PA5-44140
quantity :
100 uL
price :
US 481.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot
product information
Product Type :
Antibody
Product Name :
TEX14 Polyclonal Antibody
Catalog # :
PA5-44140
Quantity :
100 uL
Price :
US 481.00
Clonality :
Polyclonal
Purity :
Affinity Chromatography
Host :
Rabbit
Reactivity :
Human
Applications :
Western Blot: 0.2-1 ug/mL
Species :
Human
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
This gene is similar to a mouse gene that is expressed in the testis.
Immunogen :
Synthetic peptide directed towards the middle region of human TEX14
Format :
Liquid
Applications w/Dilutions :
Western Blot: 0.2-1 ug/mL
Aliases :
C85585; cancer/testis antigen 113; CT113; Inactive serine/threonine-protein kinase TEX14; LOW QUALITY PROTEIN: inactive serine/threonine-protein kinase TEX14; protein kinase-like protein SgK307; SGK307; Sugen kinase 307; testis expressed 14; testis expressed 14, intercellular bridge forming factor; testis expressed gene 14; testis expressed sequence 14; testis-expressed protein 14; Testis-expressed sequence 14; Testis-expressed sequence 14 protein; Tex14; Unknown (protein for MGC:133568)
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments